Stem cells offer great potential for the therapy of severe diseases that were previously untreatable.


Stem cells offer great potential for the therapy of severe diseases that were previously untreatable.



Kyttaro's mission is to improve the quality of care for patients suffering from diseases with high unmet medical need and orphan drug status, by developing unique treatments based on genetically modified mesenchymal stem cells.

Kyttaro's mission is to improve the quality of care for patients suffering from diseases with high unmet medical need and orphan drug status, by developing unique treatments based on genetically modified mesenchymal stem cells.


kyttaro science stem cell therapies

Mesenchymal stem cells (MSCs) and paracrine factors secreted by MSCs (growth factors, cytokines and exosomes) have great potential for acute injuries, chronic diseases and inflammatory disorders because they can orchestrate healing. After injury, MSCs paracrine factors reduce inflammation, limit scar formation, prevent cell death, modulate the immune response, stimulate new blood vessel formation and promote tissue repair.

Kyttaro Therapeutics works with CD34-negative adult stem cells, which are obtained from umbilical cord, adipose tissue or bone marrow. The aim is to use and enhance the natural properties of the stem cell through genetic modification of the MSCs.

By genetically modifying CD34-negative MSCs, these cells are used as a “Trojan Horse” to place specialized proteins, cytokines or other factors in the body where there is a need for medical therapy or to repair tissue. By combining the properties of stem cells and the action of transported proteins/cytokines, the effect is enhanced and strengthened.

Image

Kyttaro Therapeutics has a portfolio of specialized genetically modified stem cells.

Kyttaro Therapeutics has a portfolio of specialized genetically modified stem cells.


For example, one MSC has been modified to produce the acute-phase protein alpha-1 antitrypsin (AAT).

This MSC-AAT combines the beneficial effects of stem cells and AAT, making it superior to stem cell or AAT therapy alone. This has been shown in preclinical experiments for the therapy of graft versus host disease (GvHD), type 1 diabetes mellitus, and lung diseases.

Another MSC cell line produces the cytokines Il-7 and Il-12 and shows promise in CAR-T therapy

CAR-T cell therapy is a promising application for patient-specific T cells in the context of specific lymphatic/leukemic diseases. Clinically, however, this therapy is associated with significant side effects, which directly correlate with the number of applied CAR-T cells. In in vitro models it was shown that the combined application of MSC/MSC-Cyt and CAR-T cells increases the anti-tumor effect and thus, the same effect can be achieved with a reduced number of CAR-T cells. In addition, it is expected that in the context of combined therapy, the anti-inflammatory properties of genetically-modified MSCs can reduce the side effects.

An MSC third cell line produces the anti-aging protein Klotho.

Clinical studies have shown that patients who undergo an acute cardiac event or experience renal failure or neurodegenerative diseases such as Alzheimer's disease, are deficient in Klotho. Thus, an increase in the serum concentration of Klotho could have a therapeutic effect. Due to the short half-life of Klotho in serum, continuous infusion of Klotho would be necessary to increase Klotho concentrations. This can be avoided by introducing Klotho via an MSC.

Since 2007, we have developed a robust patent portfolio across three varieties of mesenchymal stem cells.


Kyttaro Therapeutics patents for genetically modified mesenchymal stem cells science

Since 2007, we have developed a robust patent portfolio across three varieties of mesenchymal stem cells.

Kyttaro Therapeutics patents for genetically modified mesenchymal stem cells science

Achievements to Date


Kyttaro Therapeutics achievements to date

Achievements to Date


Kyttaro Therapeutics achievements to date

Resources


Next steps

Next steps




Kyttaro is poised to commence clinical trials in Europe and the US for GvHD applications. We invite interested partners to contact us for more details.

Kyttaro is poised to commence clinical trials in Europe and the US for GvHD applications. We invite interested partners to contact us for more details.

Kyttaro currently is focused on two significant opportunities for MSC-AAT, with others applications for MSC-AAT and other MSCs under development:



COVID-19

MSC-AAT

GvHD

MSC-AAT